Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2022 16:30 ET | Source: Decibel Therapeutics, Inc.

Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update

- Announced positive data from interim analysis of Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy; data support continued development of DB-020 as a potential therapy...
May 17, 2022 07:30 ET | Source: Decibel Therapeutics, Inc.

Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference

BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
May 12, 2022 07:30 ET | Source: Decibel Therapeutics, Inc.

Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update

- Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of Phase 1b trial of DB-020 for cisplatin-induced hearing loss and...
March 22, 2022 07:30 ET | Source: Decibel Therapeutics, Inc.

Decibel Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
March 18, 2022 07:00 ET | Source: Decibel Therapeutics, Inc.

Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

- Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and results from interim analysis from Phase 1b trial of DB-020 for cisplatin-induced hearing loss - - Research...
February 10, 2022 16:30 ET | Source: Decibel Therapeutics, Inc.

Decibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
February 09, 2022 18:00 ET | Source: Decibel Therapeutics, Inc.

Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Across Gene Therapy Pipeline

- Podium presentation at Association for Research in Otolaryngology Annual MidWinter Meeting highlighting DB-OTO dose-ranging studies with expression analysis, functional recovery and tolerability...
January 31, 2022 07:00 ET | Source: Decibel Therapeutics, Inc.

Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting

BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
January 04, 2022 07:00 ET | Source: Decibel Therapeutics, Inc.

Decibel Therapeutics to Present at the H.C. Wainwright BioConnect Conference

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
December 06, 2021 07:30 ET | Source: Decibel Therapeutics, Inc.

Decibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from Board

BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...

Next Page keyboard_arrow_right